Quantum Genomics SA - Asset Resilience Ratio
Quantum Genomics SA (ALQGC) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Quantum Genomics SA strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how Quantum Genomics SA's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Quantum Genomics SA to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Quantum Genomics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Quantum Genomics SA market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Quantum Genomics SA maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Quantum Genomics SA Industry Peers by Asset Resilience Ratio
Compare Quantum Genomics SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
|
Concord Biotech Limited
NSE:CONCORDBIO |
Biotechnology | 18.00% |
|
Pharming Group NV
AS:PHARM |
Biotechnology | 7.13% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653 |
Biotechnology | 56.48% |
Annual Asset Resilience Ratio for Quantum Genomics SA (2012–2023)
The table below shows the annual Asset Resilience Ratio data for Quantum Genomics SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.29% | €-11.00K ≈ $-12.86K |
€3.75 Million ≈ $4.38 Million |
-0.43pp |
| 2022-12-31 | 0.14% | €32.31K ≈ $37.77K |
€23.66 Million ≈ $27.66 Million |
-24.66pp |
| 2021-12-31 | 24.80% | €5.27 Million ≈ $6.16 Million |
€21.24 Million ≈ $24.83 Million |
+8.67pp |
| 2020-12-31 | 16.13% | €5.29 Million ≈ $6.18 Million |
€32.80 Million ≈ $38.35 Million |
-19.09pp |
| 2019-12-31 | 35.21% | €5.20 Million ≈ $6.08 Million |
€14.78 Million ≈ $17.28 Million |
+35.13pp |
| 2018-12-31 | 0.09% | €16.04K ≈ $18.76K |
€18.48 Million ≈ $21.61 Million |
-71.79pp |
| 2017-12-31 | 71.88% | €10.00 Million ≈ $11.69 Million |
€13.92 Million ≈ $16.27 Million |
+32.98pp |
| 2015-12-31 | 38.90% | €4.10 Million ≈ $4.79 Million |
€10.54 Million ≈ $12.32 Million |
+38.90pp |
| 2013-12-31 | 0.00% | €-1.00 ≈ $-1.17 |
€1.69 Million ≈ $1.98 Million |
-0.15pp |
| 2012-12-31 | 0.15% | €1.59K ≈ $1.86K |
€1.06 Million ≈ $1.24 Million |
-- |
About Quantum Genomics SA
Quantum Genomics Société Anonyme is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of drugs to treat cardiovascular diseases. Quantum Genomics Société Anonyme was incorporated in 2005 and is headquartered in Paris, France.